Zobrazeno 1 - 10
of 140
pro vyhledávání: '"Ian C. Marschner"'
Publikováno v:
BMC Medical Research Methodology, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Background The classical linear model is widely used in the analysis of clinical trials with continuous outcomes. However, required model assumptions are frequently not met, resulting in estimates of treatment effect that can be inefficient
Externí odkaz:
https://doaj.org/article/30edc08481d74ae39f4a8b5b41e2e614
Autor:
Ian C. Marschner
Publikováno v:
BMC Medical Research Methodology, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background Mortality is a key component of the natural history of COVID-19 infection. Surveillance data on COVID-19 deaths and case diagnoses are widely available in the public domain, but they are not used to model time to death because the
Externí odkaz:
https://doaj.org/article/b53c8bc1a5904ce081e34e94787ba896
Autor:
Mark W. Donoghoe, Ian C. Marschner
Publikováno v:
Journal of Statistical Software, Vol 86, Iss 1, Pp 1-22 (2018)
Relative risk regression using a log-link binomial generalized linear model (GLM) is an important tool for the analysis of binary outcomes. However, Fisher scoring, which is the standard method for fitting GLMs in statistical software, may have diffi
Externí odkaz:
https://doaj.org/article/9259858ee7ec403cb7132d8407aab8d9
Autor:
Katrin M. Sjoquist, Sarah J. Lord, Michael L. Friedlander, Robert John Simes, Ian C. Marschner, Chee Khoon Lee
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 10 (2018)
Background: Progression-free survival (PFS) has been adopted as the primary endpoint in many randomized controlled trials, and can be determined much earlier than overall survival (OS). We investigated whether PFS is a good surrogate endpoint for OS
Externí odkaz:
https://doaj.org/article/e28c03ad8e674c4984293aaf73ce8a24
Autor:
Mark Jones, David Price, Jason Roberts, Joseph John, Tim Spelman, Thomas L Snelling, Vivekanand Jha, Steven Y C Tong, David Paterson, Balasubramanian Venkatesh, Naomi Hammond, James McFadyen, Robert Medcalf, Huyen Tran, Asha Bowen, Sanjeev Chunilal, Megan Rees, Joshua Davis, Justin Denholm, Susan Morpeth, Ian C Marschner, James McGree, James A Totterdell, Robert K Mahar, Bhupendra Basnet, Grace McPhee, Zoe McQuilten, Matthew O’Sullivan, Nanette Trask, Jennifer Curnow, Eileen Merriman, Todd Cooper, Julie Marsh
Publikováno v:
BMJ Medicine, Vol 2, Iss 1 (2023)
Adaptive clinical trials have designs that evolve over time because of changes to treatments or changes to the chance that participants will receive these treatments. These changes might introduce confounding that biases crude comparisons of the trea
Externí odkaz:
https://doaj.org/article/d5fb4ca321794c40b2977505be9d9985
Autor:
Mark W. Donoghoe, Ian C. Marschner
Publikováno v:
Communications in Statistics - Simulation and Computation. :1-18
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::02c90f9bf4272738e4ae5e3b8590a880
https://doi.org/10.1080/03610918.2022.2154791
https://doi.org/10.1080/03610918.2022.2154791
Publikováno v:
Statistical Methods in Medical Research. 31:2456-2469
When a clinical trial stops early for benefit, the maximum likelihood estimate (MLE) of the treatment effect may be subject to overestimation bias. Several authors have proposed adjusting for this bias using the conditional MLE, which is obtained by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e315a50b206ab66fd9b43335676f43c2
https://doi.org/10.1177/09622802221122445
https://doi.org/10.1177/09622802221122445
Autor:
Ian C Marschner, I Manjula Schou
Publikováno v:
Clinical Trials. 19:479-489
Background Adaptive platform trials allow randomized controlled comparisons of multiple treatments using a common infrastructure and the flexibility to adapt key design features during the study. Nonetheless, they have been criticized due to the pote
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d51216e2b0a964f949c3f0b8147cfd9
https://doi.org/10.1177/17407745221112001
https://doi.org/10.1177/17407745221112001
Autor:
Paul de Souza, Gary Hudes, Brian Egleston, Merryn Voysey, R. John Simes, Ian C. Marschner, Chee Khoon Lee
CCR Translation for This Article from Increase in Cholesterol Predicts Survival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b5b3eeed85d7d9e04d7e29aaaa73d23
https://doi.org/10.1158/1078-0432.22443918.v1
https://doi.org/10.1158/1078-0432.22443918.v1
Autor:
Paul de Souza, Gary Hudes, Brian Egleston, Merryn Voysey, R. John Simes, Ian C. Marschner, Chee Khoon Lee
Purpose: Temsirolimus is an effective treatment for renal cell carcinoma. It is associated with increases in serum cholesterol, triglyceride, and glucose. We investigated whether changes of these biomarkers could predict its efficacy.Experimental Des
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1b248ac02e32a86b432bdd75466623b
https://doi.org/10.1158/1078-0432.c.6520011
https://doi.org/10.1158/1078-0432.c.6520011